Does the media prefer MBOT or DCTH?

In the previous week, Microbot Medical had 11 more articles in the media than Delcath Systems. MarketBeat recorded 12 mentions for Microbot Medical and 1 mentions for Delcath Systems. Microbot Medical's average media sentiment score of 1.33 beat Delcath Systems' score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MBOT or SI?

In the previous week, Microbot Medical had 8 more articles in the media than Shoulder Innovations. MarketBeat recorded 12 mentions for Microbot Medical and 4 mentions for Shoulder Innovations. Microbot Medical's average media sentiment score of 1.33 beat Shoulder Innovations' score of 0.74 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shoulder Innovations 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELMD or MBOT?

In the previous week, Microbot Medical had 10 more articles in the media than Electromed. MarketBeat recorded 12 mentions for Microbot Medical and 2 mentions for Electromed. Microbot Medical's average media sentiment score of 1.33 beat Electromed's score of -0.82 indicating that Microbot Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MBOT or CARL?

In the previous week, Microbot Medical had 10 more articles in the media than Carlsmed. MarketBeat recorded 12 mentions for Microbot Medical and 2 mentions for Carlsmed. Microbot Medical's average media sentiment score of 1.33 beat Carlsmed's score of -0.12 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carlsmed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Microbot Medical (MBOT) Competitors

$1.80 +0.02 (+0.84%)

As of 11:02 AM Eastern

Compare

MBOT vs. DCTH, SI, ELMD, CARL, and CV

Should you buy Microbot Medical stock or one of its competitors? MarketBeat compares Microbot Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Microbot Medical include Delcath Systems (DCTH), Shoulder Innovations (SI), Electromed (ELMD), Carlsmed (CARL), and CapsoVision (CV). These companies are all part of the "medical equipment" industry.

How does Microbot Medical compare to Delcath Systems?

Microbot Medical (NASDAQ:MBOT) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Microbot Medical has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Delcath Systems has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
Delcath Systems	$85.23M	5.19	$2.70M	$0.01	1,282.50

In the previous week, Microbot Medical had 11 more articles in the media than Delcath Systems. MarketBeat recorded 12 mentions for Microbot Medical and 1 mentions for Delcath Systems. Microbot Medical's average media sentiment score of 1.33 beat Delcath Systems' score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Microbot Medical currently has a consensus price target of $6.63, indicating a potential upside of 267.04%. Delcath Systems has a consensus price target of $22.17, indicating a potential upside of 72.84%. Given Microbot Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Microbot Medical is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Delcath Systems	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Delcath Systems has a net margin of 0.62% compared to Microbot Medical's net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Delcath Systems beats Microbot Medical on 10 of the 16 factors compared between the two stocks.

How does Microbot Medical compare to Shoulder Innovations?

Microbot Medical (NASDAQ:MBOT) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Microbot Medical presently has a consensus target price of $6.63, suggesting a potential upside of 267.04%. Shoulder Innovations has a consensus target price of $21.00, suggesting a potential upside of 0.94%. Given Microbot Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Microbot Medical is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Microbot Medical has higher earnings, but lower revenue than Shoulder Innovations. Microbot Medical is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
Shoulder Innovations	$47.32M	9.12	-$40.36M	-$166.96	N/A

In the previous week, Microbot Medical had 8 more articles in the media than Shoulder Innovations. MarketBeat recorded 12 mentions for Microbot Medical and 4 mentions for Shoulder Innovations. Microbot Medical's average media sentiment score of 1.33 beat Shoulder Innovations' score of 0.74 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shoulder Innovations	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Microbot Medical has a net margin of 0.00% compared to Shoulder Innovations' net margin of -81.78%. Microbot Medical's return on equity of -21.84% beat Shoulder Innovations' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

16.3% of Microbot Medical shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Microbot Medical beats Shoulder Innovations on 10 of the 15 factors compared between the two stocks.

How does Microbot Medical compare to Electromed?

Electromed (NYSE:ELMD) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Electromed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Electromed presently has a consensus target price of $37.50, indicating a potential downside of 7.95%. Microbot Medical has a consensus target price of $6.63, indicating a potential upside of 267.04%. Given Microbot Medical's higher possible upside, analysts clearly believe Microbot Medical is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Electromed has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.70	$5.15M	$1.17	34.82
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A

In the previous week, Microbot Medical had 10 more articles in the media than Electromed. MarketBeat recorded 12 mentions for Microbot Medical and 2 mentions for Electromed. Microbot Medical's average media sentiment score of 1.33 beat Electromed's score of -0.82 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.8% of Electromed shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to Microbot Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Microbot Medical	N/A	-21.84%	-20.71%

Summary

Electromed beats Microbot Medical on 11 of the 16 factors compared between the two stocks.

How does Microbot Medical compare to Carlsmed?

Microbot Medical (NASDAQ:MBOT) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

16.3% of Microbot Medical shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Microbot Medical had 10 more articles in the media than Carlsmed. MarketBeat recorded 12 mentions for Microbot Medical and 2 mentions for Carlsmed. Microbot Medical's average media sentiment score of 1.33 beat Carlsmed's score of -0.12 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Carlsmed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Microbot Medical currently has a consensus target price of $6.63, indicating a potential upside of 267.04%. Carlsmed has a consensus target price of $18.75, indicating a potential upside of 62.55%. Given Microbot Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Microbot Medical is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Microbot Medical has higher earnings, but lower revenue than Carlsmed. Microbot Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
Carlsmed	$50.51M	6.21	-$29.63M	-$2.51	N/A

Microbot Medical has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Microbot Medical's return on equity of -21.84% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Carlsmed	-57.76%	-60.74%	-29.84%

Summary

Microbot Medical beats Carlsmed on 11 of the 15 factors compared between the two stocks.

How does Microbot Medical compare to CapsoVision?

Microbot Medical (NASDAQ:MBOT) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Microbot Medical currently has a consensus target price of $6.63, suggesting a potential upside of 267.04%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 23.28%. Given Microbot Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Microbot Medical is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Microbot Medical has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
CapsoVision	-198.87%	N/A	-136.03%

In the previous week, Microbot Medical had 12 more articles in the media than CapsoVision. MarketBeat recorded 12 mentions for Microbot Medical and 0 mentions for CapsoVision. Microbot Medical's average media sentiment score of 1.33 beat CapsoVision's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Microbot Medical	Positive
CapsoVision	Neutral

Microbot Medical has higher earnings, but lower revenue than CapsoVision. Microbot Medical is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
CapsoVision	$13.55M	25.42	-$25.32M	-$2.34	N/A

16.3% of Microbot Medical shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Microbot Medical beats CapsoVision on 11 of the 14 factors compared between the two stocks.

Get Microbot Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBOT vs. The Competition

Export

Metric	Microbot Medical	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$121.24M	$7.18B	$6.80B	$12.40B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-6.94	49.92	27.08	24.12
Price / Sales	N/A	50.88	516.47	92.58
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	1.57	6.97	10.63	6.23
Net Income	-$13.14M	$162.27M	$3.60B	$331.53M
7 Day Performance	-3.48%	-0.98%	-1.08%	-1.30%
1 Month Performance	-2.96%	-1.98%	1.28%	-1.40%
1 Year Performance	-26.33%	5.96%	24.71%	18.15%

Microbot Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBOT Microbot Medical	2.8142 of 5 stars	$1.81 +0.8%	$6.63 +267.0%	-27.5%	$121.24M	N/A	N/A	20	News Coverage Positive News
DCTH Delcath Systems	2.1921 of 5 stars	$12.87 -1.1%	$22.17 +72.2%	+11.9%	$449.13M	$85.23M	1,287.00	60
SI Shoulder Innovations	1.9768 of 5 stars	$22.38 +11.0%	$21.00 -6.2%	N/A	$418.08M	$47.32M	N/A	61
ELMD Electromed	0.6354 of 5 stars	$45.99 +0.7%	$37.50 -18.5%	+124.2%	$377.99M	$71.75M	61.32	160	Positive News
CARL Carlsmed	2.2851 of 5 stars	$12.11 +1.8%	$18.75 +54.8%	N/A	$323.50M	$50.51M	N/A	100	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBOT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Microbot Medical (MBOT) Competitors

MBOT vs. DCTH, SI, ELMD, CARL, and CV

How does Microbot Medical compare to Delcath Systems?

Summary

How does Microbot Medical compare to Shoulder Innovations?

Summary

How does Microbot Medical compare to Electromed?

Summary

How does Microbot Medical compare to Carlsmed?

Summary

How does Microbot Medical compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBOT vs. The Competition

Microbot Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Microbot Medical (MBOT) Competitors

MBOT vs. DCTH, SI, ELMD, CARL, and CV

How does Microbot Medical compare to Delcath Systems?

Which has more risk & volatility, MBOT or DCTH?

Which has higher earnings and valuation, MBOT or DCTH?

Does the media prefer MBOT or DCTH?

Do analysts rate MBOT or DCTH?

Do insiders & institutionals have more ownership in MBOT or DCTH?

Is MBOT or DCTH more profitable?

Summary

How does Microbot Medical compare to Shoulder Innovations?

Do analysts prefer MBOT or SI?

Which has stronger valuation & earnings, MBOT or SI?

Does the media favor MBOT or SI?

Is MBOT or SI more profitable?

Do insiders & institutionals hold more shares of MBOT or SI?

Summary

How does Microbot Medical compare to Electromed?

Which has more risk & volatility, ELMD or MBOT?

Do analysts recommend ELMD or MBOT?

Which has higher valuation and earnings, ELMD or MBOT?

Does the media favor ELMD or MBOT?

Do insiders & institutionals believe in ELMD or MBOT?

Is ELMD or MBOT more profitable?

Summary

How does Microbot Medical compare to Carlsmed?

Do insiders & institutionals believe in MBOT or CARL?

Does the media favor MBOT or CARL?

Do analysts recommend MBOT or CARL?

Which has higher valuation & earnings, MBOT or CARL?

Is MBOT or CARL more profitable?

Summary

How does Microbot Medical compare to CapsoVision?

Do analysts recommend MBOT or CV?

Is MBOT or CV more profitable?

Does the media prefer MBOT or CV?

Which has preferable valuation & earnings, MBOT or CV?

Do institutionals & insiders hold more shares of MBOT or CV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBOT vs. The Competition

Microbot Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools